Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: An overview of Down syndrome, autism, Fragile X and Rett syndrome

Neuroscience and Biobehavioral Reviews

Volumn 46, Issue P2, 2014, Pages 202-217

  Valenti, Daniela ^a   de Bari, Lidia ^a   De Filippis, Bianca ^b   Henrion Caude, Alexandra ^c   Vacca, Rosa Anna ^a  

^a CNR   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Autism; Down syndrome; Drug development; Epigallocatechine 3 gallate; Fragile X; Intellectual disability; Mitochondria; Mitochondrial dysfunction; Neurogenesis; Neuroplasticity; Oxidative phosphorylation; Oxidative stress; Rett syndrome

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ASCORBIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIGALLOCATECHIN GALLATE; FRAGILE X MENTAL RETARDATION PROTEIN; LEVACECARNINE; METHYL CPG BINDING PROTEIN 2; METHYLENE BLUE; MICRORNA; MITOCHONDRIAL DNA; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); THIOCTIC ACID; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; ANTIOXIDANT;

AUTISM; BIOGENESIS; BRAIN DEVELOPMENT; DEGENERATIVE DISEASE; DENDRITIC SPINE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN SYNDROME; ENERGY METABOLISM; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; INTELLECTUAL IMPAIRMENT; LEARNING DISORDER; MENTAL DEFICIENCY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; RETT SYNDROME; REVIEW; BIOLOGICAL MODEL; COMPLICATION; DRUG EFFECTS; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANTIOXIDANTS; AUTISTIC DISORDER; DOWN SYNDROME; FRAGILE X SYNDROME; HUMANS; INTELLECTUAL DISABILITY; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEUROGENESIS; NEURONAL PLASTICITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; RETT SYNDROME;

EID: 84909635812     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.01.012     Document Type: Review

References (260)

1. Alfadda, A.A., Sallam, R.M., 2012. Reactive oxygen species in health and disease. J. Biomed. Biotechnol. 936486.
2. Alvarez E., Campos-Toimil M., Justiniano-Basaran H., Lugnier C., Orallo F. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. Br. J. Pharmacol. 2006, 147:269-280.
3. Ames A. CNS energy metabolism as related to function. Brain Res. Rev. 2000, 34:42-68.
4. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
5. Anderson M.P., Hooker B.S., Herbert M.R. Bridging from cells to cognition in autism pathophysiology: biological pathways to defective brain function and plasticity. Am. J. Biochem. Biotechnol. 2008, 4:167-176.
6. Andersson U., Scarpulla R.C. Pgc-1-related coactivator, a novel, serum inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells. Mol. Cell. Biol. 2001, 21:3738-3749.
7. Antar L.N., Afroz R., Dictenberg J.B., Carroll R.C., Bassell G.J. Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J. Neurosci. 2004, 24:2648-2655.
8. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 2004, 5:725-738.
9. Arbuzova S., Hutchin T., Cuckle H. Mitochondrial dysfunction and Down's syndrome. Bioessays 2002, 24:681-684.
10. Aschrafi A., Kar A.N., Natera-Naranjo O., Macgibeny M.A., Gioio A.E., Kaplan B.B. MicroRNA-338 regulates the axonal expression of multiple nuclear-encoded mitochondrial mRNAs encoding subunits of the oxidative phosphorylation machinery. Cell Mol. Life Sci. 2012, 69:4017-4027.
11. Aschrafi A., Schwechter A.D., Mameza M.G., Natera-Naranjo O., Gioio A.E., Kaplan B.B. MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J. Neurosci. 2008, 28:12581-12590.
12. Attwell D., Laughlin S.B. An energy budget for signalling in the grey matter of the brain. J. Cereb. Blood Flow Metab. 2001, 21:1133-1145.
13. Bagni C., Greenough W.T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat. Rev. Neurosci. 2005, 6:376-387.
14. Bagni C., Tassone F., Neri G., Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J. Clin. Invest. 2012, 122:4314-4322.
15. Bajo M., Fruehauf J., Kim S.H., Fountoulakis M., Lubec G. Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down's syndrome cerebral cortex. Proteomics 2002, 2:1539-1546.
16. Bandiera S., Cartault F., Jannot A.S., Hatem E., Girard M., Rifai L., Loiseau C., Munnich A., Lyonnet S., Henrion-Caude A. Genetic variations creating MicroRNA target sites in the FXN 3'-UTR affect frataxin expression in friedreich ataxia. PLoS ONE 2013, 8:e54791.
17. Bandiera S., Rüberg S., Girard M., Cagnard N., Hanein S., Chrétien D., Munnich A., Lyonnet S., Henrion-Caude A. Nuclear outsourcing of RNA interference components to human mitochondria. PLoS ONE 2011, 6:e20746.
18. Bandiera S., Hanein S., Lyonnet S., Henrion-Caude A. Mitochondria as novel players of the cellular RNA interference. J. Biol. Chem. 2011, 286:le19.
19. Bardoni B., Davidovic L., Bensaid M., Khandjian E.W. The fragile X syndrome: exploring its molecular basis and seeking a treatment. Expert. Rev. Mol. Med. 2006, 8:1-16.
20. Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Graber S., Kovacs I., Lee W.D., Waggoner J., Cui J., White A.D., Bossy B., Martinou J.C., Youle R.J., Lipton S.A., Ellisman M.H., Perkins G.A., Bossy-Wetzel E. Nitric oxide induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006, 25:3900-3911.
21. Baseler W.A., Thapa D., Jagannathan R., Dabkowski E.R., Croston T.L., Hollander J.M. miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart. Am. J. Physiol. Cell Physiol. 2012, 303:C1244-C1251.
22. Bechara E.G., Didiot M.C., Melko M., Davidovic L., Bensaid M., Martin P., Castets M., Pognonec P., Khandjian E.W., Moine H., Bardoni B. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol. 2009, 7:e16.
23. Becker W., Sippl W. Activation, regulation, and inhibition of DYRK1A. FEBS J. 2011, 278:246-256.
24. Belichenko P.V., Wright E.E., Belichenko N.P., Masliah E., Li H.H., Mobley W.C., Francke U. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J. Comp. Neurol. 2009, 514:240-258.
25. Berman S.B., Pineda F.J., Hardwick J.M. Mitochondrial fission and fusion dynamics: the long and short of it. Cell Death Differ. 2008, 15:1147-1152.
26. Brentani H., Paula C.S., Bordini D., Rolim D., Sato F., Portolese J., Pacifico M.C., McCracken J.T. Autism spectrum disorders: an overview on diagnosis and treatment. Rev. Bras. Psiquiatr. 2013, 35(Suppl. 1):S62-S72.
27. Breuer M.E., Koopman W.J., Koene S., Nooteboom M., Rodenburg R.J., Willems P.H., Smeitink J.A. The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases. Neurobiol. Dis. 2013, 51:27-34.
28. Briggs J.A., Sun J., Shepherd J., Ovchinnikov D.A., Chung T.L., Nayler S.P., Kao L.P., Morrow C.A., Thakar N.Y., Soo S.Y., Peura T., Grimmond S., Wolvetang E.J. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells 2013, 31:467-478.
29. Brooksbank B.W., Balazs R. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res. 1984, 318:37-44.
30. Brown J.H., Johnson M.H., Paterson S.J., Gilmore R., Longhi E., Karmiloff-Smith A. Spatial representation and attention in toddlers with Williams syndrome and Down syndrome. Neuropsychologia 2003, 41:1037-1046.
31. Bruwier A., Chantrain C.F. Hematological disorders and leukemia in children with Down syndrome. Eur. J. Pediatr. 2012, 171:1301-2137.
32. Buie T., Campbell D.B., Fuchs G.J., Furuta G.T., Levy J., Vandewater J., Whitaker A.H., Atkins D., Bauman M.L., Beaudet A.L., Carr E.G., Gershon M.D., Hyman S.L., Jirapinyo P., Jyonouchi H., Kooros K., Kushak R., Levitt P., Levy S.E., Lewis J.D., Murray K.F., Natowicz M.R., Sabra A., Wershil B.K., Weston S.C., Zeltzer L., Winter H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010, 125:S19-S29.
33. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378:776-779.
34. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., Yankner B.A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002, 33:677-688.
35. Calvo S.E., Mootha V.K. The mitochondrial proteome and human disease. Annu. Rev. Genomics Hum. Genet. 2010, 11:25-44.
36. Canitano R. Epilepsy in autism spectrum disorders. Eur. Child Adolesc. Psychiatry 2007, 16:61-66.
37. Carlisle H.J., Kennedy M.B. Spine architecture and synaptic plasticity. Trends Neurosci. 2005, 28:182-187.
38. Cartault F., Munier P., Benko E., Desguerre I., Hanein S., Boddaert N., Bandiera S., Vellayoudom J., Krejbich-Trotot P., Bintner M., Hoarau J.J., Girard M., Génin E., de Lonlay P., Fourmaintraux A., Naville M., Rodriguez D., Feingold J., Renouil M., Munnich A., Westhof E., Fähling M., Lyonnet S., Henrion-Caude A. Mutation in a primate-conserved retrotransposon reveals a noncoding RNA as a mediator of infantile encephalopathy. Proc .Natl. Acad. Sci. U.S.A. 2012, 109:4980-4985.
39. Cetin Z., Yakut S., Mihci E., Manguoglu A.E., Berker S., Keser I., Luleci G. A patient with Down syndrome with a de novo derivative chromosome 21. Gene 2012, 507:159-164.
40. Chada S.R., Hollenberck P.J. Nerve growth factor signalling regulates motility and docking of axonal mitochondria. Curr. Biol. 2004, 14:1272-1276.
41. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
42. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
43. Chen Z., Li Y., Zhang H., Huang P., Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010, 29:4362-4368.
44. Cheng A., Hou Y., Mattson M.P. Mitochondria and neuroplasticity. ASN Neuro. 2010, 2:e00045.
45. Cocco T., Pacelli C., Sgobbo P., Villani G. Control of oxidative phosphorylation efficiency by complex I in brain mitochondria. Neurobiol. Aging 2009, 30:622-629.
46. Coker S.B., Melnyk A.R. Rett syndrome and mitochondrial enzyme deficiencies. J. Child Neurol. 1991, 6:164-166.
47. Coleman M., Blass J.P. Autism and lactic acidosis. J. Autism Dev. Disord. 1985, 15:1-8.
48. Contestabile A., Greco B., Ghezzi D., Tucci V., Benfenati F., Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 2013, 123:348-361.
49. Conti A., Fabbrini F., D'Agostino P., Negri R., Greco D., Genesio R., D'Armiento M., Olla C., Paladini D., Zannini M., Nitsch L. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics 2007, 8:268.
50. Cornford M.E., Philippart M., Jacobs B., Scheibel A.B., Vinters H.V. Neuropathology of Rett syndrome: case report with neuronal and mitochondrial abnormalities in the brain. J. Child Neurol. 1994, 9:424-431.
51. Coskun, P.E., Busciglio, J., 2012. Oxidative stress and mitochondrial dysfunction in Down's syndrome: relevance to aging and dementia. Curr. Gerontol. Geriatr. Res. 383170.
52. Costa V., Angelini C., D'Apice L., Mutarelli M., Casamassimi A., Sommese L., Gallo M.A., Aprile M., Esposito R., Leone L., Donizetti A., Crispi S., Rienzo M., Sarubbi B., Calabrò R., Picardi M., Salvatore P., Infante T., De Berardinis P., Napoli C., Ciccodicola A. Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21. PLoS ONE 2011, 6:e18493.
53. Costa L., Spatuzza M., D'Antoni S., Bonaccorso C.M., Trovato C., Musumeci S.A., Leopoldo M., Lacivita E., Catania M.V., Ciranna L. Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol. Psychiatry 2012, 72:924-933.
54. Cowell R.M., Blake K.R., Russell J.W. Localization of the transcriptional coactivator PGC-1α to GABAergic neurons during maturation of the rat brain. J. Comp. Neurol. 2007, 502:1-18.
55. Damiano M., Galvan L., Déglon N., Brouillet E. Mitochondria in Huntington's disease. Biochim. Biophys. Acta 2010, 1802:52-61.
56. Das S., Ferlito M., Kent O.A., Fox-Talbot K., Wang R., Liu D., Raghavachari N., Yang Y., Wheelan S.J., Murphy E., Steenbergen C. Nuclear miRNA Regulates the mitochondrial genome in the heart - novelty and significance. Cir. Res. 2012, 110:1596-1603.
57. Davidovic L., Navratil V., Bonaccorso C.M., Catania M.V., Bardoni B., Dumas M.E. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res. 2011, 21:2190-2202.
58. de Diego Otero Y., Severijnen L.A., van Cappellen G., Schrier M., Oostra B., Willemsen R. Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol. Cell Biol. 2002, 22:8332-4831.
59. de Diego-Otero Y., Romero-Zerbo Y., el Bekay R., Decara J., Sanchez L., Rodriguez-de Fonseca F., del Arco-Herrera I. α-Tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 2009, 34:1011-1026.
60. De Felice C., Maffei S., Signorini C., Leoncini S., Lunghetti S., Valacchi G., D'Esposito M., Filosa S., Della Ragione F., Butera G., Favilli R., Ciccoli L., Hayek J. Subclinical myocardial dysfunction in Rett syndrome. Eur. Heart J. Cardiovasc. Imaging 2012, 13:339-345.
61. De Felice C., Signorini C., Leoncini S., Pecorelli A., Durand T., Valacchi G., Ciccoli L., Hayek J. The role of oxidative stress in Rett syndrome: an overview. Ann. N. Y. Acad. Sci. 2012, 1259:121-135.
62. De Felice C., Signorini C., Durand T., Ciccoli L., Leoncini S., D'Esposito M., Filosa S., Oger C., Guy A., Bultel-Poncé V., Galano J.M., Pecorelli A., De Felice L., Valacchi G., Hayek J. Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. 2012, 7:447-458.
63. De Filippis B., Fabbri A., Simone D., Canese R., Ricceri L., Malchiodi-Albedi F., Laviola G., Fiorentini C. Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome. Neuropsychopharmacology 2012, 37:1152-1163.
64. de Haan J.B., Susil B., Pritchard M., Kola I. An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the gene dosage effect hypothesis. J. Neural. Transm. Suppl. 2003, 67:67-83.
65. Delabar J.M., Theophile D., Rahmani Z., Chettouh Z., Blouin J.L., Prieur M., Noel B., Sinet P.M. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur. J. Hum. Genet. 1993, 1:114-124.
66. de la Torre R., Dierssen M. Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. Prog. Brain Res. 2012, 197:1-14.
67. 2+ response element-binding protein plays a central role in the biogenesis of respiratory chain proteins in mammalian cells. IUBMB Life 2010, 62:447-452.
68. De Rasmo D., Signorile A., Larizza M., Pacelli C., Cocco T., Papa S. Activation of the cAMP cascade in human fibroblast cultures rescues the activity of oxidatively damaged complex I. Free Radic. Biol. Med. 2012, 52:757-764.
69. Dhillon S., Hellings J.A., Butler M.G. Genetics and mitochondrial abnormalities in autism spectrum disorders: a review,. Curr. Genomics 2011, 12:322-332.
70. Distelmaier F., Koopman W.J., van den Heuvel L.P., Rodenburg R.J., Mayatepek E., Willems P.H., Smeitink J.A. Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. Brain 2009, 132:833-842.
71. Dotti M.T., Manneschi L., Malandrini A., De Stefano N., Caznerale F., Federico A. Mitochondrial dysfunction in Rett syndrome. An ultrastructural and biochemical study. Brain Dev. 1993, 15:103-106.
72. Druzhyna N., Nair R.G., LeDoux S.P., Wilson G.L. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Mutat. Res. 1998, 409:81-89.
73. 2+ in cell physiology and pathophysiology. Cell Calcium 2000, 28:339-348.
74. Durand T., De Felice C., Signorini C., Oger C., Bultel-Poncé V., Guy A., Galano J.M., Leoncini S., Ciccoli L., Pecorelli A., Valacchi G., Hayek J. F(2)-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. Biochimie 2013, 95:86-90.
75. Eeg-Olofsson O., al-Zuhair A.G., Teebi A.S., Daoud A.S., Zaki M., Besisso M.S., Al-Essa M.M. Rett syndrome: a mitochondrial disease?. J. Child Neurol. 1990, 5:210-214.
76. el Bekay R., Romero-Zerbo Y., Decara J., Sanchez-Salido L., Del Arco-Herrera I., Rodríguez-de Fonseca F., de Diego-Otero Y. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. Eur. J. Neurosci. 2007, 26:3169-3180.
77. Elton T.S., Sansom S.E., Martin M.M. Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biol. 2010, 7:540-547.
78. Epstein C.J. Down's syndrome: critical genes in a critical region. Nature 2006, 441:582-583.
79. Erecinska M., Cherian S., Silver I.A. Energy metabolism in mammalian brain during development. Prog. Neurobiol. 2004, 73:397-445.
80. Esbensen A.J. Health conditions associated with aging and end of life of adults with Down syndrome. Int. Rev. Res. Ment. Retard. 2010, 39:107-126.
81. Feinstein C., Reiss A.L. Autism: the point of view from fragile X studies. J. Autism Dev. Disord. 1998, 28:393-405.
82. Forlani G., Giarda E., Ala U., Di Cunto F., Salani M., Tupler R., Kilstrup-Nielsen C., Landsberger N. The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis. Hum. Mol. Genet. 2010, 19:3114-3123.
83. Formichi P., Battisti C., Dotti M.T., Hayek G., Zappella M., Federico A. Vitamin E serum levels in Rett syndrome. J. Neurol. Sci. 1998, 156:227-230.
84. Frankland P.W., Wang Y., Rosner B., Shimizu T., Balleine B.W., Dykens E.M., Ornitz E.M., Silva A.J. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol. Psychiatry 2004, 9:417-425.
85. Frederick R.L., Shaw J.M. Moving mitochondria: establishing distribution of an essential organelle. Traffic 2007, 8:1668-1675.
86. Frustaci A., Neri M., Cesario A., Adams J.B., Domenici E., Dalla Bernardina B., Bonassi S. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic. Biol. Med. 2012, 52:2128-2141.
87. Frye R.E., Rossignol D.A. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr. Res. 2011, 69:41R-7R.
88. Frye R.E., Delatorre R., Taylor H., Slattery J., Melnyk S., Chowdhury N., James S.J. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl. Psychiatry 2013, 3:e273.
89. Fukushima N.H., Brisch E., Keegan B.R., Bleazard W., Shaw J.M. The GTPase effector domain sequence of the Dnm1p GTPase regulates self-assembly and controls a rate-limiting step in mitochondrial fission. Mol. Biol. Cell 2001, 12:2756-2766.
90. Gandhi, S., Abramov, A.Y., 2012. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell Longev. 428010.
91. Garcia-Arocena D., Hagerman P.J. Advances in understanding the molecular basis of FXTAS. Hum. Mol. Genet. 2010, 19:R83-R89.
92. Ghanizadeh A., Derakhshan N. N-Acetylcysteine for treatment of autism, a case report. J. Res. Med. Sci. 2012, 17:985-987.
93. Ghanizadeh A., Berk M., Farrashbandi H., Alavi Shoushtari A., Villagonzalo K.A. Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach. Mitochondrion 2013, 13:515-519.
94. Ghosh P., Bhaumik P., Ghosh S., Ozbek U., Feingold E., Maslen C., Sarkar B., Pramanik V., Biswas P., Bandyopadhyay B., Dey S.K. Polymorphic haplotypes of CRELD1 differentially predispose Down syndrome and euploids individuals to atrioventricular septal defect. Am. J. Med. Genet. A 2012, 158A:2843-2848.
95. Gibson G.E., Starkov A., Blass J.P., Ratan R.R., Beal M.F. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802:122-134.
96. Gibson J.H., Slobedman B., Harikrishnan K.N., Williamson S.L., Minchenko D., El-Osta A., Stern J.L., Christodoulou J. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neurosci. 2010, 11:53.
97. Grosser E., Hirt U., Janc O.A., Menzfeld C., Fischer M., Kempkes B., Vogelgesang S., Manzke T.U., Opitz L., Salinas-Riester G., Müller M. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol. Dis. 2012, 48:102-114.
98. Guedj F.C., Sébrié I., Rivals A., Ledru E., Paly J.C., Bizot D., Smith E., Rubin B., Gillet B., Arbones M., Delabar J.M. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 2009, 4:e4606.
99. Guo X., Williams J.G., Schug T.T., Li X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J. Biol. Chem. 2010, 285:13223-13232.
100. Gutsaeva D.R., Carraway M.S., Suliman H.B., Demchenko I.T., Shitara H., Yonekawa H., Piantadosi C.A. Transient hypoxia stimulates mitochondrial biogenesis in brain subcortex by a neuronal nitric oxide synthase dependent mechanism. J. Neurosci. 2008, 28:2015-2024.
101. Guy J., Hendrich B., Holmes M., Martin J.E., Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 2001, 27:322-326.
102. Haas R.H. Autism and mitochondrial disease. Dev. Disabil. Res. Rev. 2010, 16:144-153.
103. Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:61-65.
104. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994, 344:721-724.
105. Hardan A.Y., Fung L.K., Libove R.A., Obukhanych T.V., Nair S., Herzenberg L.A., Frazier T.W., Tirouvanziam R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol. Psychiatry 2012, 71:956-961.
106. Harms K.J., Rioult-Pedotti M.S., Carter D.R., Dunaevsky A. Transient spine expansion and learning-induced plasticity in layer 1 primary motor cortex. J. Neurosci. 2008, 28:5686-5690.
107. Heilstedt H.A., Shahbazian M.D., Lee B. Infantile hypotonia as a presentation of Rett syndrome. Am. J. Med. Genet. 2002, 111:238-242.
108. Helguera P., Seiglie J., Rodriguez J., Hanna M., Helguera G., Busciglio J. Adaptive downregulation of mitochondrial function in Down syndrome. Cell Metab. 2013, 17:132-140.
109. Hirst J. Towards the molecular mechanism of respiratory complex I. Biochem J. 2009, 425:327-339.
110. Hollenbeck P.J., Saxton W.M. The axonal transport of mitochondria. J. Cell Sci. 2005, 118:5411-5419.
111. Horbinski C., Chu C.T. Kinase signalling cascades in the mitochondrion: a matter of life or death. Free Radic. Biol. Med. 2005, 38:2-11.
112. Huang H., Gao Q., Peng X., Choi S.Y., Sarma K., Ren H., Morris A.J., Frohman M.A. piRNA-associated germline nuage formation and spermatogenesis require MitoPLD profusogenic mitochondrial-surface lipid signaling. Dev. Cell 2011, 20:376-387.
113. Irwin S.A., Patel B., Idupulapati M., Harris J.B., Crisostomo R.A., Larsen B.P., Kooy F., Willems P.J., Cras P., Kozlowski P.B., Swain R.A., Weiler I.J., Greenogh W.T. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet. 2001, 98:161-167.
114. Ishihara K., Amano K., Takaki E., Ebrahim A.S., Shimohata A., Shibazaki N., Inoue I., Takaki M., Ueda Y., Sago H., Epstein C.J., Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 2009, 110:1965-1976.
115. Kann O., Kovács R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007, 292:C641-C657.
116. Kaplan E.S., Cao Z., Hulsizer S., Tassone F., Berman R.F., Hagerman P.J., Pessah I.N. Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model. J. Neurochem. 2012, 123:613-621.
117. Karbowski M., Lee Y.J., Gaume B., Jeong S.Y., Frank S., Nechushtan A., Santel A., Fuller M., Smith C.L., Youle R.J. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J. Cell Biol. 2002, 159:931-938.
118. Kaufmann W.E., Moser H.W. Dendritic anomalies in disorders associated with mental retardation. Cereb. Cortex 2000, 10:981-991.
119. Kaufmann W.E., Tierney E., Rohde C.A., Suarez-Pedraza M.C., Clarke M.A., Salorio C.F., Bibat G., Bukelis I., Naram D., Lanham D.C., Naidu S. Social impairments in Rett syndrome: characteristics and relationship with clinical severity. J. Intellect. Disabil. Res. 2012, 56:233-247.
120. Kempermann G., Wiskott L., Gage F.H. Functional significance of adult neurogenesis. Curr. Opin. Neurobiol. 2004, 14:186-191.
121. Kirkland R.A., Franklin J.L. Bax, reactive oxygen, and cytochrome c release in neuronal apoptosis. Antioxid. Redox Signal. 2003, 5:589-596.
122. Kishida K.T., Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid. Redox Signall. 2007, 9:233-244.
123. Kitamura T., Saitoh Y., Takashima N., Murayama A., Niibori Y., Ageta H., Sekiguchi M., Sugiyama H., Inokuchi K. Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory. Cell 2009, 139:814-827.
124. Klinge C.M. Estrogenic control of mitochondrial function and biogenesis. J. Cell. Biochem. 2008, 105:1342-1351.
125. Ko Y.H., Delannoy M., Hullihen J., Chiu W., Pedersen P.L. Mitochondrial ATP synthasome. Cristae-enriched membranes and a multiwell detergent screening assay yield dispersed single complexes containing the ATP synthase and carriers for Pi and ADP/ATP. J. Biol. Chem. 2003, 278:12305-12319.
126. Koopman W.J., Nijtmans L.G., Dieteren C.E., Roestenberg P., Valsecchi F., Willems J.A., Smeitink P.H. Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation. Antioxid. Redox Signal. 2010, 12:1431-1470.
127. Koshiba T., Detmer S.A., Kaiser J.T., Chen H., McCaffery J.M., Chan D.C. Structural basis of mitochondrial tethering by mitofusin complexes. Science 2004, 305:858-862.
128. Kovacic P., Somanathan R. Redox processes in neurodegenerative disease involving reactive oxygen species. Curr. Neuropharmacol. 2012, 10:289-302.
129. Krakowiak P., Goodlin-Jones B., Hertz-Picciotto I., Croen L.A., Hansen R.L. Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-based study. J. Sleep Res. 2008, 17:197-206.
130. Krauss, S., 2001. Mitochondria: structure and role in respiration. Encyclopedia of Life Sciences, http://www.med.ufro.cl/clases_apuntes/cs_preclinicas/mg-fisica-medica/sub-modulo-1/Mitochondria.pdf.
131. Kriaucionis S., Paterson A., Curtis J., Guy J., Macleod N., Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol. Cell Biol. 2006, 26:5033-5042.
132. Kuhn D.E., Nuovo G.J., Terry A.V., Martin M.M., Malana G.E., Sansom S.E., Pleister A.P., Beck W.D., Head E., Feldman D.S., Elton T.S. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J. Biol. Chem. 2010, 285:1529-1543.
133. Landi S., Putignano E., Boggio E.M., Giustetto M., Pizzorusso T., Ratto G.M. The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. Sci. Rep. 2011, 1:45.
134. Latham K.E., Sapienza C., Engel N. The epigenetic lorax: gene-environment interactions in human health. Epigenomics 2012, 4:383-402.
135. Lee C.W., Peng H.B. The function of mitochondria in presynaptic development at the neuromuscular junction. Mol. Biol. Cell 2008, 19:150-158.
136. Lee S.H., Lee S., Jun H.S., Jeong H.J., Cha W.T., Cho Y.S., Kim J.H., Ku S.Y., Cha K.Y. Expression of the mitochondrial ATPase6 gene and Tfam in Down syndrome. Mol. Cells 2003, 15:181-185.
137. Leehey M.A., Hagerman P.J. Fragile X-associated tremor/ataxia syndrome. Handb. Clin. Neurol. 2012, 103:373-386.
138. Legesse-Miller A., Massol R.H., Kirchhausen T. Constriction and Dnm1p recruitment are distinct processes in mitochondrial fission. Mol. Biol. Cell 2003, 14:1953-1963.
139. Leoncini S., De Felice C., Signorini C., Pecorelli A., Durand T., Valacchi G., Ciccoli L., Hayek J. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 2011, 16:145-153.
140. Levy M., Faas G.C., Saggau P., Craigen W.J., Sweatt J.D. Mitochondrial regulation of synaptic plasticity in the hippocampus. J. Biol. Chem. 2003, 278:17727-17734.
141. Li J., Donath S., Li Y., Qin D., Prabhakar B.S., Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010, 6:e1000795.
142. Li Z., Okamoto K., Hayashi Y., Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119:873-887.
143. Lioy D.T., Garg S.K., Monaghan C.E., Raber J., Foust K.D., Kaspar B.K., Hirrlinger P.G., Kirchhoff F., Bissonnette J.M., Ballas N., Mandel G. A role for glia in the progression of Rett's syndrome. Nature 2011, 475:497-500.
144. Liu Q.A., Shio H. Mitochondrial morphogenesis, dendrite development, and synapse formation in cerebellum require both Bcl-w and the glutamate receptor delta2. PLoS Genet. 2008, 4:e1000097.
145. Loane, M., Morris, J.K., Addor, M.C., Arriola, L., Budd, J., Doray, B., Garne, E., Gatt, M., Haeusler, M., Khoshnood, B., Klungsøyr, Melve, K, Latos-Bielenska, A., McDonnell, B., Mullaney, C., O'Mahony, M., Queisser-Wahrendorf, A., Rankin, J., Rissmann, A., Rounding, C., Salvador, J,. Tucker, D., Wellesley, D., Yevtushok, L., Dolk, H., 2013. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur. J. Hum. Genet. 21, 27-33.
146. Lombard J. Autism: a mitochondrial disorder?. Med. Hypotheses 1998, 50:497-500.
147. Lott I.T. Neurological phenotypes for Down syndrome across the life span. Prog. Brain Res. 2012, 197:101-121.
148. Lott I.T. Antioxidants in Down syndrome. Biochim. Biophys. Acta 2012, 1822:657-663.
149. Lott I.T., Doran E., Nguyen V., Tournay A., Head E., Gillen D.L. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am. J. Med. Genet. Part A 2011, 155:1939-1948.
150. Lott I.T., Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:172-178.
151. Lucas E.K., Dougherty S.E., McMeekin L.J., Trinh A.T., Reid C.S., Cowell R.M. Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α. PLoS ONE 2012, 7:e42878.
152. Marsit C.J., Eddy K., Kelsey K.T. MicroRNA responses to cellular stress. Cancer Res. 2006, 66:10843-10848.
153. Mattick, J.S., Makunin, I.V., 2006. Non-coding RNA. Hum. Mol. Genet. 15, Spec No 1, R17-R29.
154. Mattson M.P., Partin J. Evidence for mitochondrial control of neuronal polarity. J. Neurosci. Res. 1999, 56:8-20.
155. Mattson M.P. Mitochondrial regulation of neuronal plasticity. Neurochem. Res. 2007, 32:707-715.
156. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
157. McBride H.M., Neuspiel M., Wasiak S. Mitochondria: more than just a powerhouse. Curr. Biol 2006, 16:R551-R560.
158. Millan M.J. An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 2013, 68:2-82.
159. Miller K.E., Sheetz M.P. Axonal mitochondrial transport and potential are correlated. J. Cell Sci. 2004, 117:2791-2804.
160. Mironov S.L., Skorova E.Y., Kügler S. Epac-mediated cAMP-signalling in the mouse model of Rett Syndrome. Neuropharmacology 2011, 60:869-877.
161. Misiak B., Leszek J., Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull. 2012, 89:144-149.
162. Miyashiro K.Y., Beckel-Mitchener A., Purk T.P., Becker K.G., Barret T., Liu L., Carbonetto S., Weiler I.J., Greenough W.T., Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 2003, 37:417-431.
163. Moretti P., Levenson J.M., Battaglia F., Atkinson R., Teague R., Antalffy B., Armstrong D., Arancio O., Sweatt J.D., Zoghbi H.Y. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J. Neurosci. 2006, 26:319-327.
164. Muchová J., Sustrová M., Garaiová I., Liptáková A., Blazícek P., Kvasnicka P., Pueschel S., Duracková Z. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic. Biol. Med. 2001, 31:499-508.
165. Naidu S., Kaufmann W.E., Abrams M.T., Pearlson G.D., Lanham D.C., Fredericksen K.A., Barker P.B., Horska A., Golay X., Mori S., Wong D.F., Yablonski M., Moser H.W., Johnston M.V. Neuroimaging studies in Rett syndrome. Brain Dev. 2001, 1:S62-S71.
166. Napolioni V., Persico A.M., Porcelli V., Palmieri L. The mitochondrial aspartate/glutamate carrier AGC1 and calcium homeostasis: physiological links and abnormalities in autism. Mol. Neurobiol. 2011, 44:83-92.
167. Natelson B.H. Brain dysfunction as one cause of CFS symptoms including difficulty with attention and concentration. Front. Physiol 2013, 4:109.
168. Noji H., Yoshida M. The rotary machine in the cell, adenosine-5'-triphosphate synthase. J. Biol. Chem. 2001, 276:1665-1668.
169. Ok W.J., Cho H.J., Kim H.H., Lee D.H., Kang H.Y., Kwon H.W., Rhee M.H., Kim M., Park H.J. Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. J. Atheroscler. Thromb. 2012, 19:337-348.
170. Osakada F., Hashino A., Kume T., Katsuki H., Kaneko S., Akaike A. Neuroprotective effects of alpha-tocopherol on oxidative stress in rat striatal cultures. Eur. J. Pharmacol. 2003, 465:15-22.
171. Overly C.C., Rieff H.I., Hollenberck P.J. Organelle motility and metabolism in axons vs dendrites of cultured hippocampal neurons. J. Cell Sci. 1996, 109:971-980.
172. Pagano G., Castello G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv. Exp. Med. Biol. 2012, 724:291-299.
173. Pagliarini D.J., Calvo S.E., Chang B., Sheth S.A., Vafai S.B., Ong S.E., Walford G.A., Sugiana C., Boneh A., Chen W.K., Hill D.E., Vidal M., Evans J.G., Thorburn D.R., Carr S.A., Mootha V.K. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008, 134:112-123.
174. Palmieri L., Persico A.M. Mitochondrial dysfunction in autism spectrum disorders: cause or effect?. Biochim. Biophys. Acta 2010, 1797:1130-1137.
175. Papa S., De Rasmo D. Complex I deficiencies in neurological disorders. Trends Mol. Med. 2013, 19:61-69.
176. Papa S., Scacco S., Sardanelli A.M., Petruzzella V., Vergari R., Signorile A., Technikova-Dobrova Z. Complex I and the cAMP cascade in human physiopathology. Biosci. Rep. 2002, 22:3-16.
177. Penagarikano O., Mulle J.G., Warren S.T. The pathophysiology of fragile X syndrome. Annu. Rev. Genomics Hum. Genet. 2007, 8:109-129.
178. Perluigi M., Butterfield D.A. Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012, 724904.
179. Persico A., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006, 29:349-358.
180. Piccoli C., Scrima R., Ripoli M., Di Ianni M., Del Papa B., D'Aprile A., Quarato G., Martelli M.P., Servillo G., Ligas C., Boffoli D., Tabilio A., Capitanio N. Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production. Stem Cells 2008, 26:2843-2854.
181. Picker J.D., Walsh C.A. New innovations: therapeutic opportunities for intellectual disabilities. Ann. Neurol. 2013, 74:382-390.
182. Popov V., Medvedev N.I., Davies H.A., Stewart M.G. Mitochondria form a filamentous reticular network in hippocampal dendrites but are present as discrete bodies in axons: a three-dimensional ultrastructural study. J. Comp. Neurol. 2005, 492:50-65.
183. Pritchard M.A., Kola I. The gene dosage effect hypothesis versus the amplified developmental instability hypothesis in Down syndrome. J. Neural. Transm. Suppl. 1999, 57:293-303.
184. Pugazhenthi S., Phansalkar K., Audesirk G., West A., Cabell L. Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic. Biol. Med. 2006, 40:21-34.
185. Puisségur M.P., Mazure N.M., Bertero T., Pradelli L., Grosso S., Robbe-Sermesant K., Maurin T., Lebrigand K., Cardinaud B., Hofman V., Fourre S., Magnone V., Ricci J.E., Pouysségur J., Gounon P., Hofman P., Barbry P., Mari B. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011, 18:465-478.
186. Rachidi M., Lopes C. Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms. Neurosci. Res 2007, 59:349-369.
187. Rachidi M., Lopes C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur. J. Paediatr. Neurol. 2008, 12:168-182.
188. Raha S., Robinson B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 2000, 25:502-508.
189. Reiss A.L., Freund L. Fragile X syndrome, DSM-III-R, and autism. J. Am. Acad. Child Adolesc. Psychiatry 1990, 29:885-891.
190. Renton J.P., Xu N., Clark J.J., Hansen M.R. Interaction of neurotrophin signaling with Bcl-2 localized to the mitochondria and endoplasmic reticulum on spiral ganglion neuron survival and neurite growth. J. Neurosci. Res. 2010, 88:2239-2251.
191. Rhein V., Song X., Wiesner A., Ittner L.M., Baysang G., Meier F., Ozmen L., Bluethmann H., Dröse S., Brandt U., Savaskan E., Czech C., Götz J., Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20057-20062.
192. Ricceri L., De Filippis B., Laviola G. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 2008, 19:501-517.
193. Ricceri L., De Filippis B., Laviola G. Rett syndrome treatment in mouse models: Searching for effective targets and strategies. Neuropharmacology 2013, 68:106-115.
194. Rice S.E., Gelfand V.I. Paradigm lost: milton connects kinesin heavy chain to miro on mitochondria. J. Cell Biol. 2006, 173:459-461.
195. Risch N., Spiker D., Lotspeich L., Nouri N., Hinds D., Hallmayer J., Kalaydjieva L., McCague P., Dimiceli S., Pitts T., Nguyen L., Yang J., Harper C., Thorpe D., Vermeer S., Young H., Hebert J., Lin A., Ferguson J., Chiotti C., Wiese-Slater S., Rogers T., Salmon B., Nicholas P., Petersen P.B., Pingree C., McMahon W., Wong D.L., Cavalli-Sforza L.L., Kraemer H.C., Myers R.M. A genomic screen of autism: evidence for a multilocus etiology. Am. J. Hum. Genet. 1999, 65:493-507.
196. Rojas J.C., Bruchey A.K., Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol. 2011, 96:32-45.
197. Roper R.J., Reeves R.H. Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006, 2:e50.
198. Rossignol D.A., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol. Psychiatry 2012, 17:290-314.
199. Ross-Inta C., Omanska-Klusek A., Wong S., Barrow C., Garcia-Arocena D., Iwahashi C., Berry-Kravis E., Hagerman R.J., Hagerman P.J., Giulivi C. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome Catherine. Biochem. J. 2010, 429:545-552.
200. Rubenstein J.L., Merzenich M.M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003, 2:25-267.
201. Ruparelia A., Pearn M.L., Mobley W.C. Aging and intellectual disability: Insights from mouse models of down syndrome. Dev. Disabil. Res. Rev. 2013, 18:43-50.
202. Ruthel G., Hollenbeck P.J. Response of mitochondrial traffic to axon determination and differential branch growth. J. Neurosci. 2003, 23:8618-8624.
203. Sai Y., Zou Z., Peng K., Dong Z. The Parkinson's disease-related genes act in mitochondrial homeostasis. Neurosci. Biobehav. Rev. 2012, 36:2034-2043.
204. Sanmann J.N., Schaefer G.B., Buehler B.A., Sanger W.G. Algorithmic approach for methyl-CpG binding protein 2 (MECP2) gene testing in patients with neurodevelopmental disabilities. J. Child Neurol. 2012, 27:346-354.
205. Saugstad J.A. MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J. Cereb. Blood Flow. Metab. 2010, 30:1564-1576.
206. Saywell V., Viola A., Confort-Gouny S., Le Fur Y., Villard L., Cozzone P.J. Brain magnetic resonance study of Mecp2 deletion effects on anatomy and metabolism. Biochem. Biophys. Res. Commun. 2006, 340:776-783.
207. Scarpulla R.C. Nuclear activators and coactivators in mammalian mitochondrial biogenesis,. Biochim. Biophys. Acta 2002, 1576:1-14.
208. Scarpulla R.C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta 2011, 1813:1269-1278.
209. Schaefer G.B., Mendelsohn N.J. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet. Med. 2008, 10:4-12.
210. Schroeder E.K., Kelsey N.A., Doyle J., Breed E., Bouchard R.J., Loucks F.A., Harbison R.A., Linseman D.A. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid. Redox Signal. 2009, 11:469-480.
211. Serasinghe M.N., Yoon Y. The mitochondrial outer membrane protein hFis1 regulates mitochondrial morphology and fission through self-interaction. Exp. Cell Res. 2008, 314:3494-3507.
212. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., Armstrong D., Paylor R., Zoghbi H. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 2002, 35:243-254.
213. Shetty P.K., Galeffi F., Turner D.A. Cellular links between neuronal activity and energy homeostasis. Front. Pharmacol. 2012, 3:43.
214. Shin J.H., Weitzdoerfer R., Fountoulakis M., Lubec G. Expression of cystathionine beta-synthase, pyridoxal kinase, and ES1 protein homolog (mitochondrial precursor) in fetal Down syndrome brain. Neurochem. Int. 2004, 45:73-79.
215. Shukkur E.A., Shimohata A., Akagi T., Yu W., Yamaguchi M., Murayama M., Chui D., Takeuchi T., Amano K., Subramhanya K.H., Hashikawa T., Sago H., Epstein C.J., Takashima A., Yamakawa K. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 2006, 15:2752-2762.
216. Sierra C., Vilaseca M.A., Brandi N., Artuch R., Mira A., Nieto M., Pineda M. Oxidative stress in Rett syndrome. Brain Dev. 2001, 1:S236-S239.
217. Siew W.H., Tan K.L., Babaei M.A., Cheah P.S., Ling K.H. MicroRNAs and intellectual disability (ID) in Down syndrome, X-linked ID, and Fragile X syndrome. Front. Cell Neurosci. 2013, 7:41.
218. Silver I., Erecinska M. Oxygen and ion concentrations in normoxic and hypoxic brain cells. Adv. Exp. Med. Biol. 1998, 454:7-16.
219. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82:1807-1821.
220. Sinha S. Anti-oxidant gene expression imbalance, aging and Down syndrome. Life Sci. 2005, 76:1407-1426.
221. Solmaz S.R., Hunte C. Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer. J. Biol. Chem. 2008, 283:17542-17549.
222. Srividhya R., Zarkovic K., Stroser M., Waeg G., Zarkovic N., Kalaiselvi P. Mitochondrial alterations in aging rat brain: effective role of (-)-epigallo catechin gallate. Int. J. Dev. Neurosci. 2009, 27:223-231.
223. Takashima S., Iida K., Mito T., Arima M. Dendritic and histochemical development and ageing in patients with Down's syndrome. J. Intellect. Disabil. Res. 1994, 38:265-273.
224. Tang G., Gutierrez Rios P., Kuo S.H., Akman H.O., Rosoklija G., Tanji K., Dwork A., Schon E.A., Dimauro S., Goldman J., Sulzer D. Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol. Dis. 2013, 54:349-361.
225. Telford J.E., Kilbride S.M., Davey G.P. Complex I is rate-limiting for oxygen consumption in the nerve terminal. J. Biol. Chem. 2009, 284:9109-9114.
226. Tiano L., Busciglio J. Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10)?. Biofactors 2011, 37:386-392.
227. 2+ signaling. J. Cell. Mol. Med. 2000, 4:164-175.
228. Tomitsuka E., Kita K., Esumi H. Regulation of succinate-ubiquinone reductase and fumarate reductase activities in human complex II by phosphorylation of its flavoprotein subunit. Proc. Jpn. Acad. Ser. B: Phys. Biol. Sci. 2009, 885:258-265.
229. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552:335-344.
230. Twig G., Hyde B., Shirihai O.S. Mitochondrial fusion, fission and autophagy as a quality control axis: The bioenergetic view. Biochim. Biophys. Acta 2008, 1777:1092-1097.
231. Urdinguio R.G., Lopez-Serra L., Lopez-Nieva P., Alaminos M., Diaz-Uriarte R., Fernandez A.F., Esteller M. Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS ONE 2008, 3:e3669.
232. Valenti D., Tullo A., Caratozzolo M.F., Merafina R.S., Scartezzini P., Marra E., Vacca R.A. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. Biochem. J. 2010, 431:299-310.
233. Valenti D., Manente G.A., Moro L., Marra E., Vacca R.A. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem. J. 2011, 435:679-688.
234. Valenti D., De Rasmo D., Signorile A., Rossi L., de Bari L., Scala I., Granese B., Papa S., Vacca R.A. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. Biochim. Biophys. Acta 2013, 1832:542-552.
235. Van Cleve S.N., Cannon S., Cohen W.I. Part II: Clinical Practice Guidelines for adolescents and young adults with Down Syndrome: 12 to 21 Years. J. Pediatr. Health Care 2006, 20:198-205.
236. Van Cleve S.N., Cohen W.I. Part I: clinical practice guidelines for children with Down syndrome from birth to 12 years. J. Pediatr. Health Care 2006, 20:47-54.
237. Verstreken P., Ly C.V., Venken K.J., Koh T.W., Zhou Y., Bellen H.J. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at drosophila neuromuscular junctions. Neuron 2005, 47:365-478.
238. Vicari S., Bellucci S., Carlesimo G.A. Visual and spatial long-term memory: differential pattern of impairments in Williams and Down syndromes. Dev. Med. Child Neurol. 2005, 47:305-311.
239. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005, 39:359-407.
240. Wallace D.C. Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. Annu. Rev. Biochem. 2007, 76:781-821.
241. Wallace D.C., Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion 2010, 10:12-31.
242. Wang H., Yuan G., Prabhakar N.R., Boswell M., Katz D.M. Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling. J. Neurochem. 2006, 96:694-705.
243. Wang W., Fang H., Groom L., Cheng A., Zhang W., Liu J., Wang X., Li K., Han P., Zheng M., Yin J., Wang W., Mattson M.P., Kao J.P., Lakatta E.G., Sheu S.S., Ouyang K., Chen J., Dirksen R.T., Cheng H. Superoxide flashes in single mitochondria. Cell 2008, 134:279-290.
244. Wang W., Groom L., Cheng A., Yin J., Mattson M.P., Kao J.P.Y., Lakatta E.G., Sheu S.S., Dirksen R.T., Cheng H. Redox flashes in single mitochondria. Cell 2008, 134:279-290.
245. Weick J.P., Held D.L., Bonadurer G.F., Doers M.E., Liu Y., Maguire C., Clark A., Knackert J.A., Molinarolo K., Musser M., Yao L., Yin Y., Lu J., Zhang X., Zhang S.C., Bhattacharyya A. Deficits in human trisomy 21 iPSCs and neurons. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9962-9967.
246. Weissman J.R., Kelley R.I., Bauman M.L., Cohen B.H., Murray K.F., Mitchell R.L., Kern R.L., Natowicz M.R. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS ONE 2008, 3:e3815.
247. Wen Y., Li W., Poteet E.C., Xie L., Tan C., Yan L.J., Ju X., Liu R., Qian H., Marvin M.A., Goldberg M.S., She H., Mao Z., Simpkins J.W., Yang S.H. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 2011, 286:16504-16515.
248. Westerman B. Mitochondrial fusion and fission in cell life and death. Nat. Rev. Mol. Cell Biol. 2010, 11:872-884.
249. Willers I.M., Martínez-Reyes I., Martínez-Diez M., Cuezva J.M. miR-127-5p targets the 3'UTR of human beta-F1-ATPase mRNA and inhibits its translation. Biochim. Biophys. Acta 2012, 1817:838-848.
250. Wong R.O., Ghosh A. Activity-dependent regulation of dendritic growth and patterning. Nat. Rev. Neurosci. 2002, 3:803-812.
251. Wu Z., Huang X., Feng Y., Handschin C., Gullicksen P.S., Bare O., Labow M., Spiegelman B., Stevenson S.C. Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1α transcription and mitochondrial biogenesis in muscle cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14379-14384.
252. Yamamoto H., Morino K., Nishio Y., Ugi S., Yoshizaki T., Kashiwagi A., Maegawa H. MicroRNA-494 regulates mitochondrial biogenesis in skeletal muscle through mitochondrial transcription factor A and Forkhead box j3. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E1419-E1427.
253. Yang E.J., Ahn Y.S., Chung K.C. Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J. Biol. Chem. 2001, 276:39819-39824.
254. Yao A., Jin S., Li X., Liu Z., Ma X., Tang J., Zhang Y.Q. Drosophila FMRP regulates microtubule network formation and axonal transport of mitochondria. Hum. Mol. Genet. 2011, 20:51-63.
255. Young J.I., Hong E.P., Castle J.C., Crespo-Barreto J., Bowman A.B., Rose M.F., Kang D., Richman R., Johnson J.M., Berget S., Zoghbi H.Y. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17551-17558.
256. Yu T., Fox R.J., Burwell L.S., Yoon Y. Regulation of mitochondrial fission and apoptosis by the mitochondrial outer membrane protein hFis1. J. Cell Sci. 2005, 118:4141-4151.
257. Yuste R., Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu. Rev. Neurosci. 2001, 24:1071-1089.
258. Zachariah R.M., Rastegar M. Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research. Neural. Plast. 2012, 415825.
259. Zana M., Janka Z., Kálmán J. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging 2007, 28:648-676.
260. Zoghbi H.Y. Rett syndrome: what do we know for sure?. Nat. Neurosci. 2009, 12:239-240.